CRISPR Therapeutics AG (NASDAQ:CRSP - Get Free Report) hit a new 52-week low during mid-day trading on Tuesday . The stock traded as low as $32.96 and last traded at $34.03, with a volume of 3968336 shares changing hands. The stock had previously closed at $36.99.
Analyst Ratings Changes
Several research firms have weighed in on CRSP. Royal Bank of Canada decreased their price target on shares of CRISPR Therapeutics from $53.00 to $48.00 and set a "sector perform" rating on the stock in a research report on Wednesday, February 12th. The Goldman Sachs Group decreased their target price on CRISPR Therapeutics from $66.00 to $57.00 and set a "neutral" rating on the stock in a report on Thursday, February 13th. HC Wainwright restated a "buy" rating and issued a $65.00 price target on shares of CRISPR Therapeutics in a research report on Thursday, February 13th. JMP Securities reaffirmed a "market outperform" rating and issued a $86.00 price objective on shares of CRISPR Therapeutics in a research note on Thursday, February 13th. Finally, Bank of America reduced their target price on shares of CRISPR Therapeutics from $98.00 to $85.00 and set a "buy" rating for the company in a report on Tuesday, January 7th. Two investment analysts have rated the stock with a sell rating, nine have given a hold rating and eleven have issued a buy rating to the stock. According to data from MarketBeat.com, CRISPR Therapeutics currently has an average rating of "Hold" and an average target price of $73.11.
Check Out Our Latest Stock Report on CRISPR Therapeutics
CRISPR Therapeutics Price Performance
The company's 50-day simple moving average is $42.15 and its 200 day simple moving average is $44.64. The firm has a market cap of $2.72 billion, a P/E ratio of -7.23 and a beta of 1.85.
CRISPR Therapeutics (NASDAQ:CRSP - Get Free Report) last issued its quarterly earnings data on Tuesday, February 11th. The company reported ($0.44) earnings per share (EPS) for the quarter, beating analysts' consensus estimates of ($1.15) by $0.71. CRISPR Therapeutics had a negative return on equity of 18.46% and a negative net margin of 981.54%. Analysts anticipate that CRISPR Therapeutics AG will post -5.16 EPS for the current fiscal year.
Insiders Place Their Bets
In related news, General Counsel James R. Kasinger sold 2,850 shares of the company's stock in a transaction dated Tuesday, March 11th. The shares were sold at an average price of $42.42, for a total transaction of $120,897.00. Following the transaction, the general counsel now directly owns 77,530 shares in the company, valued at approximately $3,288,822.60. This represents a 3.55 % decrease in their position. The sale was disclosed in a document filed with the SEC, which is accessible through this hyperlink. Also, CEO Samarth Kulkarni sold 9,973 shares of the business's stock in a transaction that occurred on Tuesday, March 11th. The shares were sold at an average price of $42.42, for a total value of $423,054.66. Following the transaction, the chief executive officer now owns 180,890 shares of the company's stock, valued at $7,673,353.80. This trade represents a 5.23 % decrease in their position. The disclosure for this sale can be found here. Insiders sold 32,381 shares of company stock valued at $1,608,243 over the last three months. 4.10% of the stock is owned by company insiders.
Institutional Trading of CRISPR Therapeutics
Large investors have recently made changes to their positions in the stock. Magnetar Financial LLC purchased a new stake in CRISPR Therapeutics in the 4th quarter valued at about $359,000. Capital Market Strategies LLC bought a new position in CRISPR Therapeutics in the fourth quarter worth approximately $461,000. KBC Group NV increased its holdings in CRISPR Therapeutics by 2,047.4% during the 4th quarter. KBC Group NV now owns 60,514 shares of the company's stock worth $2,382,000 after purchasing an additional 57,696 shares during the period. Raymond James Financial Inc. bought a new stake in CRISPR Therapeutics during the 4th quarter valued at $3,231,000. Finally, Geode Capital Management LLC lifted its holdings in shares of CRISPR Therapeutics by 3.6% in the 3rd quarter. Geode Capital Management LLC now owns 1,008,214 shares of the company's stock worth $47,383,000 after buying an additional 35,196 shares during the period. 69.20% of the stock is owned by hedge funds and other institutional investors.
About CRISPR Therapeutics
(
Get Free Report)
CRISPR Therapeutics is a gene-editing company focused on developing transformative gene-based medicines for serious diseases using its proprietary CRISPR/Cas9 platform. CRISPR/Cas9 is a revolutionary gene-editing technology that allows for precise, directed changes to genomic DNA. CRISPR Therapeutics has established a portfolio of therapeutic programs across a broad range of disease areas including hemoglobinopathies, oncology, regenerative medicine and rare diseases.
Further Reading
Before you consider CRISPR Therapeutics, you'll want to hear this.
MarketBeat keeps track of Wall Street's top-rated and best performing research analysts and the stocks they recommend to their clients on a daily basis. MarketBeat has identified the five stocks that top analysts are quietly whispering to their clients to buy now before the broader market catches on... and CRISPR Therapeutics wasn't on the list.
While CRISPR Therapeutics currently has a Hold rating among analysts, top-rated analysts believe these five stocks are better buys.
View The Five Stocks Here
Like this article? Share it with a colleague.
Link copied to clipboard.
